Glenmark, Evestra ink deal to develop generic NuvaRing

Glenmark Pharmaceuticals and Evestra said today that the companies inked a development, license and commercialization deal for a generic version of Merck’s NuvaRing. Development of the etonogestrel/ethinyl estradiol contraceptive is under way, according to the companies, and they plan to file an Abbreviated New Drug Application in fiscal 2019. Get the full story at our sister site, Drug Delivery Business News. The post Glenmark, Evestra ink deal to develop generic NuvaRing appeared first on MassDevice.
Source: Mass Device - Category: Medical Equipment Authors: Tags: Drug-Device Combinations Research & Development Wall Street Beat Women's Health Evestra Glenmark Pharmaceuticals Source Type: news